Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan

Background: Enfortumab vedotin (EV), an innovative antibody–drug conjugate targeting Nectin-4, has emerged as a breakthrough therapy for locally advanced or metastatic urothelial carcinoma (la/mUC). However, EV-related cutaneous toxicity (EVRCT) remains a significant concern because of Nectin-4 expr...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Y. Kita, T. Hara, T. Kawahara, K. Hashimoto, Y. Matsushita, H. Ito, T. Abe, A. Igarashi, S. Shimura, T. Sazuka, A. Yokomizo, N. Takaoka, M. Kato, T. Hazama, M. Miyake, Y. Sugino, J. Mutaguchi, A. Takahashi, Y. Shiraishi, S. Tatarano, Y. Takai, T. Mochizuki, S. Nakanishi, K. Mori, T. Yoshida, T. Hayashi, H. Otsuka, T. Anami, K. Okasho, K. Daizumoto, M. Kobayashi, I. Kobayashi, J. Watanabe, N. Nishiyama, T. Shibuya, Y. Matsui, H. Nishiyama, H. Kitamura, T. Kobayashi
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-03-01
Serie:	ESMO Real World Data and Digital Oncology
Ämnen:	EV-related cutaneous toxicity incidence risk factor clinical outcome
Länkar:	http://www.sciencedirect.com/science/article/pii/S2949820124000729
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!